09:27 EDT Valneva (VALN) drops 2% to $6.05 after UK restricts vaccine use
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VALN:
- Valneva Announces Positive Phase 2 Results for Chikungunya Vaccine in Children
- Valneva says IXCHIQ ‘well tolerated’ by children ages 1-11 years
- Valneva Prepares for Shareholder Meeting and Announces Leadership Change
- Valneva to Engage with Investors at June Conferences
- Valneva’s Chikungunya Vaccine Use Paused for Elderly Amid Safety Review